Biotech firm Immutep jumps on positive study results for cancer therapy
24/04/2024 04:09
** Shares of Australian biotechnology firm Immutep Ltd
IMM.AX rise as much as 11.7% to A$0.430, highest level since
March 24, 2022
** Best intraday gain since March 5 this year
** Announces positive preliminary topline results from
TACTI-003 phase IIB trial to evaluate drug therapy to treat head
and neck squamous cell carcinoma
** Second-biggest gainer in the ASX All Ordinaries index
.AORD
** More than 7.8 mln shares change hands, vs the 30-day
average of 1.1 mln shares
** Stock trims some gains to trade 10.4% higher at A$0.425
as of 0220 GMT
** IMM up 11.6% so far this year, as of last close
(Reporting by Sameer Manekar in Bengaluru)
((Sameer.Manekar@thomsonreuters.com; Twitter: https://twitter.com/sameer_manekar))